TrialCancer letters2026

A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling.

Natalie K Horvat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.